Cornea

A Q&A with PPP Committee Cornea/External Disease Panel member Daniel S. Choi, MD.

A discussion with Shigeru Kinoshita, MD, PhD; and Edward J. Holland, MD.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The therapy improved vision, reduced central corneal thickness, and demonstrated strong safety, offering an alternative to corneal transplants.

Corneal confocal microscopy, semaglutide therapy offer treatment options

A study led by researchers at the University of Birmingham finds AI-powered models can match ophthalmologists in diagnosing infectious keratitis, offering promise for global eye care improvements.

According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial. The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients.

According to the company, in a confirmatory trial, Epioxa met pre-specified primary efficacy endpoint and exhibited positive tolerability and safety profiles through 12 months, supporting an anticipated NDA submission by the end of 2024.

A Norwegian study demonstrates that transplant rates continue to drop over time

The trial is assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

In a study, a team of Chinese researchers looked at the mechanisms behind the development of EI and explored effective treatment options.

Vyznova is for the treatment of bullous keratopathy of the cornea, a sight-threatening and debilitating condition affecting the endothelial cells of the cornea.

TEPEZZA is the first and only medicine approved in Japan to treat active TED.

The new standard: Stabilizing keratoconus and improving vision.

Prevent Blindness is offering free resources to help educate the public and allied healthcare professionals on the many types of inflammatory eye diseases, and steps that should be taken to prevent vision loss.

Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful improvements across [multiple] key disease endpoints at the primary efficacy analysis timepoint of 15 weeks.”

The team conducted a cross-sectional study from December 2016 to March 2024 in patients with acute infectious conjunctivitis

In a study, Australian ophthalmology and optometry researcher and Beatles fan Professor Stephen Vincent has analyzed John Lennon’s little-known, hit-and-miss use of contact lenses in the 1960s and found the Rock and Roll Hall of Famer was probably right when he theorized that his cannabis use helped them stay in place.

Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.

As a medical student at the University of Miami Miller School of Medicine, Ashlyn Anzu Gary landed the unique opportunity to help launch an interdisciplinary clinical research program exploring hypnotherapy as a treatment for people with chronic eye pain.

The trial will evaluate VRDN-001, an intravenously delivered monoclonal antibody that acts as a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R).

Investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata

Claes H. Dohlman, MD, PhD, has been recognized globally as the founding father of modern corneal science, He was instrumental in driving research investigations to help better understand the structure and function of the cornea.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

IKA Keratoconus Symposium and Controversies in Modern Eye Care shone brightly in May

From amniotic membrane grafting to neurotization.

Plasma emission for blepharitis, meibomian gland dysfunction, and dry eye disease.

Phase 1 multicenter study demonstrates early signs of efficacy.

Optimizing corneal neurotization outcomes with cryopreserved amniotic membrane.

Researchers found that blocking the interaction between peptide and receptor using topical applications of naltrexone reverses dry eye symptoms in 5 days and restores tear fluid volumes to normal baseline.

Two randomized, double-masked, placebo-controlled, Phase 3 trials named REVEAL-1 and REVEAL-2 are expected to start in August 2024.